Physician profile
Robert Lemon
NPI 1992867147
$7,223.91
in general payments reported to CMS, 2019-2025
54 companies · $44.96 in 2025
The $44.96 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,554 · 2020: $2,222 · 2021: $1,202 · 2022: $1,631 · 2023: $389 · 2024: $181 · 2025: $44.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $615.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $615.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,537.79 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $1,128.66 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $398.11 | 2019-2025 | |
| Celgene Corporation | $374.71 | 2021-2024 | Opdualag, Pomalyst |
| Astrazeneca Pharmaceuticals Lp | $323.43 | 2019-2022 | |
| Exelixis INC. | $269.17 | 2019-2022 | |
| Glaxosmithkline, LLC. | $245.47 | 2019-2023 | Zejula |
| Pharmacyclics LLC, An Abbvie Company | $214.79 | 2019-2023 | Epkinly, Imbruvica |
| Amgen INC. | $190.39 | 2019-2022 | |
| Octapharma USA, INC. | $186.53 | 2019 | |
| Shire North American Group INC | $150.76 | 2019 | |
| Seagen INC. | $143.93 | 2019-2021 | |
| Daiichi Sankyo INC. | $141.23 | 2020-2022 | |
| Janssen Biotech, INC. | $132.53 | 2021-2022 | |
| Genentech USA, INC. | $132.02 | 2019-2022 |
Show all 53 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lemon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.